IPO registrations (S-1, F-1) · Registrants
KIORA PHARMACEUTICALS INC
- SEC CIK
- 1372514 · filings on EDGAR ↗
- Former names
- EYEGATE PHARMACEUTICALS INC (2006–2021)
- Registration
- Form S-1, first filed 2014-07-30, last 2023-06-01; 8 initial registrations, 21 amendments
- Outcome
- Final prospectus filed 2015-02-13; declared effective 2015-02-12; withdrawal requested 2016-10-31
- Industry (SIC)
- Pharmaceutical Preparations 2834
- Incorporated in
- DE
- Business address
- 169 SAXONY RD., SUITE 212, Encinitas, CA 92024
- EIN
- 98-0443284
- Ticker
- KPRX, KPHMW (Nasdaq, OTC)
- EDGAR entity type
- operating
- Insiders and CEO pay
- KIORA PHARMACEUTICALS INC on the corporate pages
Offering terms
- Final price
- $6.00 per share (424B4 filed 2015-02-13, an initial public offering)
- Shares sold
- 683,250
- Gross proceeds
- $4,099,500 before underwriting discounts and any over-allotment option
- Listing
- OTCQB under the symbol EYEG
- Lead underwriters
- Aegis Capital (341,625 shares)
- Syndicate
- Chardan (341,625)
Read from the cover pages of the filings listed under “Prospectus pages read” below; check the document for anything that matters.
On this site
- Form 5500 plan sponsor: KIORA PHARMACEUTICALS, INC. EXACT (EIN (EXACT))
- Form D issuer: KIORA PHARMACEUTICALS INC EXACT (CIK (EXACT))
- SEC filer: EYEGATE PHARMACEUTICALS INC EXACT (CIK (EXACT))
Filings 50
| Filed | Form | What it is | Name as filed | EDGAR |
|---|---|---|---|---|
| 2014-07-30 | S-1 | S-1 (registration) | EYEGATE PHARMACEUTICALS INC | 0001144204-14-045707 ↗ |
| 2014-08-08 | S-1/A | S-1/A (amendment) | EYEGATE PHARMACEUTICALS INC | 0001144204-14-048143 ↗ |
| 2014-08-29 | S-1/A | S-1/A (amendment) | EYEGATE PHARMACEUTICALS INC | 0001144204-14-053333 ↗ |
| 2014-09-12 | S-1/A | S-1/A (amendment) | EYEGATE PHARMACEUTICALS INC | 0001144204-14-055714 ↗ |
| 2014-09-29 | S-1/A | S-1/A (amendment) | EYEGATE PHARMACEUTICALS INC | 0001144204-14-058162 ↗ |
| 2014-11-20 | S-1/A | S-1/A (amendment) | EYEGATE PHARMACEUTICALS INC | 0001144204-14-070114 ↗ |
| 2014-12-02 | S-1/A | S-1/A (amendment) | EYEGATE PHARMACEUTICALS INC | 0001144204-14-071658 ↗ |
| 2014-12-24 | S-1/A | S-1/A (amendment) | EYEGATE PHARMACEUTICALS INC | 0001144204-14-075901 ↗ |
| 2015-01-26 | S-1/A | S-1/A (amendment) | EYEGATE PHARMACEUTICALS INC | 0001144204-15-003738 ↗ |
| 2015-02-04 | S-1/A | S-1/A (amendment) | EYEGATE PHARMACEUTICALS INC | 0001144204-15-005804 ↗ |
| 2015-02-12 | EFFECT | EFFECT (declared effective) | EYEGATE PHARMACEUTICALS INC | 9999999995-15-000404 ↗ |
| 2015-02-13 | 424B4 | 424B4 (final prospectus) | EYEGATE PHARMACEUTICALS INC | 0001144204-15-009184 ↗ |
| 2015-06-05 | S-1 | S-1 (registration) | EYEGATE PHARMACEUTICALS INC | 0001144204-15-035843 ↗ |
| 2015-07-15 | S-1/A | S-1/A (amendment) | EYEGATE PHARMACEUTICALS INC | 0001144204-15-042717 ↗ |
| 2015-07-28 | S-1/A | S-1/A (amendment) | EYEGATE PHARMACEUTICALS INC | 0001144204-15-044597 ↗ |
| 2015-07-30 | S-1/A | S-1/A (amendment) | EYEGATE PHARMACEUTICALS INC | 0001144204-15-044920 ↗ |
| 2015-07-30 | S-1/A | S-1/A (amendment) | EYEGATE PHARMACEUTICALS INC | 0001144204-15-045116 ↗ |
| 2015-07-30 | EFFECT | EFFECT (declared effective) | EYEGATE PHARMACEUTICALS INC | 9999999995-15-002115 ↗ |
| 2015-07-31 | 424B4 | 424B4 (final prospectus) | EYEGATE PHARMACEUTICALS INC | 0001144204-15-045565 ↗ |
| 2016-05-06 | EFFECT | EFFECT (declared effective) | EYEGATE PHARMACEUTICALS INC | 9999999995-16-004571 ↗ |
| 2016-10-31 | RW | RW (withdrawal request) | EYEGATE PHARMACEUTICALS INC | 0001144204-16-130563 ↗ |
| 2017-04-21 | S-1 | S-1 (registration) | EYEGATE PHARMACEUTICALS INC | 0001144204-17-021542 ↗ |
| 2017-05-05 | S-1/A | S-1/A (amendment) | EYEGATE PHARMACEUTICALS INC | 0001144204-17-024866 ↗ |
| 2017-06-05 | S-1/A | S-1/A (amendment) | EYEGATE PHARMACEUTICALS INC | 0001144204-17-031012 ↗ |
| 2017-06-08 | S-1MEF | S-1MEF (added securities) | EYEGATE PHARMACEUTICALS INC | 0001144204-17-031800 ↗ |
| 2017-06-08 | EFFECT | EFFECT (declared effective) | EYEGATE PHARMACEUTICALS INC | 9999999995-17-001483 ↗ |
| 2017-06-12 | 424B4 | 424B4 (final prospectus) | EYEGATE PHARMACEUTICALS INC | 0001144204-17-032033 ↗ |
| 2018-03-23 | S-1 | S-1 (registration) | EYEGATE PHARMACEUTICALS INC | 0001571049-18-000192 ↗ |
| 2018-04-09 | S-1/A | S-1/A (amendment) | EYEGATE PHARMACEUTICALS INC | 0001144204-18-019713 ↗ |
| 2018-04-12 | EFFECT | EFFECT (declared effective) | EYEGATE PHARMACEUTICALS INC | 9999999995-18-000816 ↗ |
| 2018-04-16 | 424B4 | 424B4 (final prospectus) | EYEGATE PHARMACEUTICALS INC | 0001144204-18-020581 ↗ |
| 2019-05-13 | EFFECT | EFFECT (declared effective) | EYEGATE PHARMACEUTICALS INC | 9999999995-19-001106 ↗ |
| 2019-11-18 | EFFECT | EFFECT (declared effective) | EYEGATE PHARMACEUTICALS INC | 9999999995-19-002598 ↗ |
| 2021-04-30 | EFFECT | EFFECT (declared effective) | EYEGATE PHARMACEUTICALS INC | 9999999995-21-001694 ↗ |
| 2022-05-03 | S-1 | S-1 (registration) | KIORA PHARMACEUTICALS INC | 0001104659-22-055297 ↗ |
| 2022-07-13 | S-1/A | S-1/A (amendment) | KIORA PHARMACEUTICALS INC | 0001104659-22-079591 ↗ |
| 2022-07-19 | S-1/A | S-1/A (amendment) | KIORA PHARMACEUTICALS INC | 0001104659-22-080880 ↗ |
| 2022-07-21 | S-1/A | S-1/A (amendment) | KIORA PHARMACEUTICALS INC | 0001104659-22-081271 ↗ |
| 2022-07-21 | EFFECT | EFFECT (declared effective) | KIORA PHARMACEUTICALS INC | 9999999995-22-002123 ↗ |
| 2022-07-25 | 424B1 | 424B1 (final prospectus) | KIORA PHARMACEUTICALS INC | 0001104659-22-082104 ↗ |
| 2022-12-22 | S-1 | S-1 (registration) | KIORA PHARMACEUTICALS INC | 0001104659-22-129237 ↗ |
| 2022-12-28 | EFFECT | EFFECT (declared effective) | KIORA PHARMACEUTICALS INC | 9999999995-22-003657 ↗ |
| 2023-02-03 | S-1 | S-1 (registration) | KIORA PHARMACEUTICALS INC | 0001104659-23-010675 ↗ |
| 2023-02-13 | EFFECT | EFFECT (declared effective) | KIORA PHARMACEUTICALS INC | 9999999995-23-000410 ↗ |
| 2023-05-05 | S-1 | S-1 (registration) | KIORA PHARMACEUTICALS INC | 0001628280-23-016198 ↗ |
| 2023-05-12 | S-1/A | S-1/A (amendment) | KIORA PHARMACEUTICALS INC | 0001628280-23-017953 ↗ |
| 2023-06-01 | S-1/A | S-1/A (amendment) | KIORA PHARMACEUTICALS INC | 0001372514-23-000085 ↗ |
| 2023-06-01 | EFFECT | EFFECT (declared effective) | KIORA PHARMACEUTICALS INC | 9999999995-23-001605 ↗ |
| 2023-06-02 | 424B1 | 424B1 (final prospectus) | KIORA PHARMACEUTICALS INC | 0001372514-23-000090 ↗ |
| 2024-03-28 | EFFECT | EFFECT (declared effective) | KIORA PHARMACEUTICALS INC | 9999999995-24-000765 ↗ |
Prospectus pages read 2
| Filed | Form | Read as | Range | Price | Shares | Proceeds | Listing | Underwriters | What was found | Document |
|---|---|---|---|---|---|---|---|---|---|---|
| 2015-02-04 | S-1/A | registration statement | $6.00 | 833,333 | $4,999,998 | OTCQB EYEG | 2 | primary document; price sentence, shares headline, proceeds computed, cover names 2 | document ↗ | |
| 2015-02-13 | 424B4 | final prospectus | $6.00 | 683,250 | $4,099,500 | OTCQB EYEG | 2 | primary document; price sentence, shares headline, proceeds table, underwriting table 2, cover names 2 | document ↗ |
Officers, directors and large holders Forms 3, 4 and 5
| Insider | Role | Title | Filings | Years | On this site |
|---|---|---|---|---|---|
| BALLAND THOMAS | Director | 8 | 2015–2017 | ||
| CHANEY PAUL G | Director | 15 | 2015–2023 | ||
| Chaoui Mounia | Director | 7 | 2015–2016 | ||
| FCPR VENTECH B | TenPercentOwner | 2 | 2015 | ||
| FROM STEPHEN | Director,Officer; Director,Officer,TenPercentOwner; Officer | Executive Chairman; President and CEO | 51 | 2015–2022 | |
| GOLDBERG MORTON | Director | 18 | 2015–2021 | ||
| HANCOCK THOMAS | Director | 12 | 2015–2021 | ||
| IPSA (INNOVEN PARTENAIRES S.A.) | TenPercentOwner | 2 | 2015 | ||
| MALFROY-CAMINE BERNARD | Director | 12 | 2015–2021 | ||
| MANZO MICHAEL P. | Officer | Vice President of Engineering; VP of Engineering | 41 | 2015–2021 | |
| NATIXIS PRIVATE EQUITY | TenPercentOwner | 2 | 2015 | ||
| TYLE PRAVEEN | Director | 19 | 2015–2026 | ||
| Ventech Capital II | TenPercentOwner | 5 | 2015–2017 | ||
| Mann Brenda | Officer | VP of Research & Development | 39 | 2016–2021 | |
| Wirostko Barbara | Officer | Chief Medical Officer | 17 | 2016–2019 | |
| Brenneman Ryan Randall | Officer | Chief Financial Officer | 3 | 2016 | |
| Romano Sarah | Officer | Chief Financial Officer; Interim CFO | 43 | 2017–2022 | |
| Garanzini Michael | Officer | Chief Commercial Officer | 5 | 2017–2018 | |
| ARMISTICE CAPITAL, LLC | Director,TenPercentOwner; TenPercentOwner | 18 | 2018–2021 | ||
| Armistice Capital Master Fund Ltd. | Director,TenPercentOwner; TenPercentOwner | 18 | 2018–2021 | ||
| Boyd Steven | Director,TenPercentOwner; TenPercentOwner | 18 | 2018–2021 | ||
| Greenleaf Peter | Director | 3 | 2018–2019 | ||
| Maher Illya Keith | Director | 1 | 2020 | ||
| Obermayr Franz | Officer | Acting CEO | 2 | 2021 | |
| Shapiro Aron | Director | 9 | 2021–2026 | ||
| Gayron Kenneth L | Director | 5 | 2021–2023 | ||
| Strem Brian M. | Director,Officer | President and CEO | 14 | 2021–2026 | |
| Daniels Eric Joseph | Officer | Chief Development Officer | 13 | 2021–2026 | |
| Hollander David | Director | 7 | 2021–2026 | ||
| Parsons Erin | Director | 8 | 2022–2026 | ||
| Drexler Susan L. | Officer | Interim CFO | 1 | 2022 | |
| Tosca Melissa | Officer | CFO; EVP Finance; EVP of Finance | 11 | 2022–2026 | |
| Stengone Carmine N. | Director | 6 | 2023–2026 | ||
| Walters-Hoffert Lisa | Director | 5 | 2024–2026 | ||
| Lane Keith J. | Other | 2 | 2026 |
Everyone who filed an insider report for this company, from the SEC’s Insider Transactions Data Sets (2006 on). Person pages are matched by name and state only.
Private offerings before or after (Form D)
| First filed | Issuer | Industry | Offering | Sold | Investors | Filings |
|---|---|---|---|---|---|---|
| 2026-04-21 | KIORA PHARMACEUTICALS INC | Pharmaceuticals | $5,000,000 | $5,000,000 | 3 | 1 |
| 2024-02-14 | KIORA PHARMACEUTICALS INC | Pharmaceuticals | $15,000,000 | $15,000,000 | 13 | 1 |
| 2023-02-17 | KIORA PHARMACEUTICALS INC | Pharmaceuticals | $10,000,000 | $0 | 1 | 1 |
| 2023-02-17 | KIORA PHARMACEUTICALS INC | Pharmaceuticals | $200,000 | $200,000 | 1 | 1 |
| 2021-11-04 | EYEGATE PHARMACEUTICALS INC | Pharmaceuticals | Indefinite | $67,258 | 6 | 1 |
| 2021-08-23 | EYEGATE PHARMACEUTICALS INC | Pharmaceuticals | $10,750,013 | $10,750,013 | 14 | 1 |
| 2021-01-21 | EYEGATE PHARMACEUTICALS INC | Pharmaceuticals | $8,000,003 | $8,000,003 | 1 | 1 |
| 2021-01-04 | EYEGATE PHARMACEUTICALS INC | Pharmaceuticals | Indefinite | $3,203,083 | 15 | 1 |
| 2020-01-15 | EYEGATE PHARMACEUTICALS INC | Pharmaceuticals | Indefinite | $0 | 5 | 1 |
| 2019-10-08 | EYEGATE PHARMACEUTICALS INC | Pharmaceuticals | $1,875,000 | $1,875,000 | 1 | 1 |
| 2016-07-07 | EYEGATE PHARMACEUTICALS INC | Pharmaceuticals | $3,768,750 | $3,768,750 | 2 | 1 |
| 2016-03-21 | EYEGATE PHARMACEUTICALS INC | Pharmaceuticals | $2,618,797 | $2,618,797 | 32 | 1 |
| 2014-07-24 | EYEGATE PHARMACEUTICALS INC | Biotechnology | $2,000,000 | $994,843 | 18 | 1 |
Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Company details are what EDGAR holds today, not at the time of the filing.
Also on this site Fuzzy
| Record | Name as filed | Where | Dataset | Matched by |
|---|---|---|---|---|
| Plan sponsor | KIORA PHARMACEUTICALS, INC. | CA | Form 5500 (employee benefit plans) | EIN (EXACT) |
| Form D issuer | KIORA PHARMACEUTICALS INC | CA | Form D private offerings | CIK (EXACT) |
| SEC filer | KIORA PHARMACEUTICALS INC | SEC filers (EDGAR) | CIK (EXACT) | |
| Trademark owner | KIORA PHARMACEUTICALS, INC. | CA | Trademarks (USPTO) | name and state |
| Form 5500 plan sponsor | KIORA PHARMACEUTICALS, INC. | EIN (EXACT) |
Matched by an identifier (EIN, CIK, CRD), by name and state or city, or by street address; a shared name or address is not proof of the same person or organization. Every link says how it was made; how the cross-referencing works.
Others with the same interests
SIC industry Pharmaceutical Preparations, CA first:
- NovaCardia Inc CA
- MyoKardia, Inc. CA
- Bioquest Corp CA
- Regen BioPharma Inc CA
- CONNETICS CORP CA
- SIBIA NEUROSCIENCES INC CA
- MEDIVATION, INC. CA
- IMMUSOL INC CA
- DYNAVAX TECHNOLOGIES CORP CA
- Diadexus, Inc. CA
In other datasets, the same topic (Health) in CA:
- Nonprofit: 24 HOUR CANCER DANCE-A-THON (Nonprofits (IRS Form 990))
Interests: Pharmaceutical Preparations · Health